Please click any link below for our Business-related articles.

"Arteaus launches with $18M from Atlas, OrbiMed - licenses a molecule from Eli Lilly for migraine"
(FierceBiotech)

"Arteaus Therapeutics, LLC Raises $18M to Prevent Migraines - Arteaus, using a virtual team and collaborating with Lilly's Chorus unit, will develop an antibody through Phase 2 trials."
(FierceBiotech)

"A More Rational Approach to New-Product Development"
(Harvard Business Review)

"Lilly Sings a New Tune: Chorus Unit Brings High Efficiency Note to Early R&D"
(The Pink Sheet)

"Lilly's Chorus Experiment"
(In Vivo)

"Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept"
(Start-Up)

"Pharma 2020: The vision. Which path will you take?"
(PriceWaterhouseCoopers)

"Transforming Drug Development - A Fully Outsourced Model"
(Pharma Focus Asia - Issue 9)

"An Audience With....Steven Paul"
(Macmillian Pub, January 2009, Volume 8)

"Transforming Drug Development with a Fully Outsourced Model"
(Pharmaceutical Outsourcing May-June 2009)


Please click any link below for our Scientific-related articles.

"SAFETY, TOLERABILITY AND EVIDENCE OF EFFICACY OF INTRAVENOUS LY2439821 IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BACKGROUND ORAL DMARDs"
(2009)

"Phase 2 Study of Safety and Efficacy of a novel anti-BAFF Monoclonal Antibody, in Patients (Pts) with RA Treated with Methotrexate (MTX)"
(2009)

"LY2439821, a novel anti-IL-17 mAb: Safety,tolerability and efficacy in patients with RA on background DMARDs"
(2009)